Omeros (OMER) Competitors $4.29 +0.13 (+3.13%) Closing price 04:00 PM EasternExtended Trading$4.30 +0.00 (+0.12%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OMER vs. PCRX, NKTR, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, and BMYShould you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Bristol Myers Squibb (BMY). These companies are all part of the "pharmaceuticals" industry. Omeros vs. Its Competitors Pacira BioSciences Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol Myers Squibb Omeros (NASDAQ:OMER) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Which has more volatility and risk, OMER or PCRX? Omeros has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Which has better valuation and earnings, OMER or PCRX? Pacira BioSciences has higher revenue and earnings than Omeros. Pacira BioSciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmerosN/AN/A-$156.82M-$2.11-2.03Pacira BioSciences$700.97M1.74-$99.56M-$2.78-9.79 Does the media refer more to OMER or PCRX? In the previous week, Pacira BioSciences had 3 more articles in the media than Omeros. MarketBeat recorded 9 mentions for Pacira BioSciences and 6 mentions for Omeros. Pacira BioSciences' average media sentiment score of 1.56 beat Omeros' score of 1.50 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate OMER or PCRX? Omeros presently has a consensus target price of $18.00, indicating a potential upside of 319.58%. Pacira BioSciences has a consensus target price of $30.83, indicating a potential upside of 13.27%. Given Omeros' stronger consensus rating and higher possible upside, equities analysts plainly believe Omeros is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Pacira BioSciences 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Do insiders & institutionals believe in OMER or PCRX? 48.8% of Omeros shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 12.9% of Omeros shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is OMER or PCRX more profitable? Omeros has a net margin of 0.00% compared to Pacira BioSciences' net margin of -18.08%. Pacira BioSciences' return on equity of 13.29% beat Omeros' return on equity.Company Net Margins Return on Equity Return on Assets OmerosN/A N/A -55.49% Pacira BioSciences -18.08%13.29%6.61% SummaryOmeros and Pacira BioSciences tied by winning 8 of the 16 factors compared between the two stocks. Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMER vs. The Competition Export to ExcelMetricOmerosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$283.11M$11.00B$5.75B$9.77BDividend YieldN/A1.84%6.66%4.50%P/E Ratio-2.0321.6182.5826.38Price / SalesN/A31.30535.42110.80Price / CashN/A25.1325.7028.92Price / Book-1.283.4511.196.58Net Income-$156.82M$211.94M$3.28B$265.84M7 Day Performance-2.05%-1.16%0.15%-0.07%1 Month Performance18.84%13.38%8.34%5.83%1 Year Performance1.90%-8.99%54.21%17.88% Omeros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMEROmeros3.8836 of 5 stars$4.29+3.1%$18.00+319.6%-1.2%$283.11MN/A-2.03210News CoveragePositive NewsPCRXPacira BioSciences3.1328 of 5 stars$25.36-1.9%$30.83+21.6%+71.4%$1.16B$700.97M-9.12720News CoveragePositive NewsNKTRNektar Therapeutics3.8829 of 5 stars$27.14+0.4%$88.33+225.5%+55.5%$514.07M$98.43M-3.09220Positive NewsGap DownASMBAssembly Biosciences3.4249 of 5 stars$26.62-1.2%$38.67+45.3%+51.9%$206.61M$28.52M-4.77100Positive NewsShort Interest ↑CPIXCumberland Pharmaceuticals0.644 of 5 stars$3.26-0.9%N/A+158.5%$49.22M$37.87M-14.8280Gap DownLLYEli Lilly and Company5 of 5 stars$696.08-2.2%$950.17+36.5%-23.7%$673.57B$45.04B45.5047,000Trending NewsAnalyst UpgradeAnalyst RevisionJNJJohnson & Johnson4.6126 of 5 stars$178.53-0.4%$176.29-1.3%+6.8%$431.79B$88.82B19.09138,100Positive NewsABBVAbbVie4.6344 of 5 stars$207.58-1.4%$214.95+3.6%+7.1%$372.04B$56.33B98.8555,000MRKMerck & Co., Inc.4.9971 of 5 stars$85.43-2.2%$107.44+25.8%-29.0%$218.23B$64.17B13.1675,000Positive NewsPFEPfizer4.8049 of 5 stars$25.15-2.8%$28.12+11.8%-14.7%$147.14B$63.63B13.3881,000Trending NewsBMYBristol Myers Squibb4.5608 of 5 stars$47.15-1.6%$56.38+19.6%-5.6%$97.54B$48.30B19.0134,100Positive News Related Companies and Tools Related Companies PCRX Alternatives NKTR Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OMER) was last updated on 9/2/2025 by MarketBeat.com Staff From Our Partners2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAmerica Betrayed Porter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OMER Stock Alerts